Fadogia agrestis to Improve Testosterone - Quick Reference Sheet
evipedia.aidev
← Back

Fadogia agrestis to Improve Testosterone

Created on 08/10/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

Fadogia agrestis is a traditional West African stem botanical sold for testosterone and male vitality. Large testosterone and mating-behavior rises appear only in short-course rat data; longer rat dosing showed testicular, liver, and kidney biochemical stress. No human trials confirm effect or safety. Protocols often use 300–600 mg with cycling and labs; retail product chemistry often fails. (Full Review)

Protocol

Dose
300–600 mg/day
Stem extract/powder; ~300 mg/day as the lower safer band
Timing
Once daily, morning
No food-effect or circadian data; single daily dosing is standard
Cycling
8–12 wk on / 2–4 wk off
Or ~3 weeks on / 1 week off to limit continuous exposure
Time to effect
Testosterone (animal)
Within days
Short-course rodent serum testosterone rises
Possible human effect
Weeks
Uncontrolled reports; no controlled human timeline
Lab recheck
4–8 weeks
More informative than day-to-day subjective swings

Benefits

Contraindications
  • Pregnancy and lactation
  • Known allergy to Rubiaceae family plants or to the product
  • Active significant liver disease (e.g., Child-Pugh class B–C cirrhosis or decompensated hepatic failure) or significant kidney disease (e.g., eGFR <30 mL/min/1.73 m² or chronic kidney disease stage 4–5)
  • Hormone-sensitive prostate cancer under active management unless oncology/endocrinology clears use
  • Adolescents
    •
Key Interactions
  • Exogenous testosterone / anabolic-androgenic steroids (e.g., testosterone cypionate, nandrolone)
  • hCG, clomiphene, enclomiphene, kisspeptin-pathway agents
  • Other testosterone-support botanicals (tongkat ali / Eurycoma longifolia, fenugreek, ashwagandha, boron, DHEA)
  • PDE5 inhibitors (sildenafil, tadalafil)
  • Hepatotoxic or nephrotoxic drugs (high-dose acetaminophen, certain antifungals such as ketoconazole or fluconazole, NSAIDs such as ibuprofen or naproxen in susceptible patients)
  • Anticoagulants / antiplatelets (e.g., warfarin, apixaban, aspirin, clopidogrel)
    •

Risk & Side Effects

  • Medium: Product adulteration and label inaccuracy
    •
  • Low: Testicular biochemical stress with prolonged high-dose exposure; liver and kidney membrane injury signals
    •
  • Speculative: Unknown human adverse-event profile; interference with intended testosterone benefit via cytotoxicity
    •

Monitoring

Marker Target Why
Total testosterone (morning) Often ~500–900+ ng/dL (lab-specific) Primary efficacy signal
Free testosterone Upper half of lab reference Bioavailable androgen
LH Mid-normal, not suppressed Checks axis still “on”
FSH Lab reference mid-range Spermatogenic axis
Estradiol (sensitive) Context-dependent mid-range for men Aromatization balance
SHBG Lab reference; interpret with free testosterone Binding capacity
GGT Low-normal Membrane/liver stress marker from rat data
Alkaline phosphatase Lab reference Liver/bone/testicular enzyme signal in rat work
ALT, AST Low-normal Hepatocellular injury screen
Creatinine / eGFR eGFR ≥90 mL/min/1.73 m² preferred Kidney filtration
CBC (hematocrit) Hematocrit typically <50–52% Androgen-related erythropoiesis

Cadence: Baseline before first dose; recheck at 4–8 weeks of a cycle, then each new cycle or every 3–6 months if intermittent use continues

Qualitative Assessment

  • Morning energy and motivation
  • Libido and sexual function
  • Training recovery and strength trend
  • Mood stability
  • Absence of new right-upper-quadrant discomfort, dark urine, or unexplained fatigue (possible hepatic warning signs)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.